Crinetics Pharmaceuticals Inc (CRNX) Company Profile & Statistics

Crinetics Pharmaceuticals Inc
CRNX
(Nasdaq - US)
Closed
54.79
-4.87 (-8.16%)
in:usd•As of: Nov 15, 2024 15:59 UTC -5
Pre Market:0+0.00 (0.00%)
Open
59.84
High
59.96
Low
54.42

About Crinetics Pharmaceuticals Inc

CEO

R. Scott Struthers

Headquarters

6055 lusk boulevard

san diego, ca 92121, united states

Auditor

BDO USA, P.C.

Employees

290

Share Holders

Website

www.crinetics.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States.

Crinetics Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	5.08B
Enterprise Value	4.78B
Enterprise Value/EBITDA (ttm)	-16.58
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	6.09
Price to Sales (ttm)	1.07K
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	75.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	-11406.08%
Return on Equity (ttm)	-36.12%
Return on Invested Capital (ttm)	-38.20%
Return on Assets (ttm)	-31.89%

Income Statement

Revenue (ttm)	1.39M
Revenue Per Share (ttm)	0.02
Gross Profit (ttm)	1.39M
EBITDA (ttm)³	-288.27M
Net Income Avi to Common (ttm)	-258.54M
Diluted EPS (ttm)	-3.73

Share Statistics

Beta (5Y Monthly)	0.62
52-Week Change	81.30%
S&P500 52-Week Change	29.10%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	80.04M
Dividend Yield	0.00%
Float ⁴	87.17M
% Held by Insiders	6.00%
% Held by Institutions	98.51%

Balance Sheet

Total Cash (mrq)	862.95M
Total Cash Per Share (mrq)	10.78
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	16.09%
Quick Ratio (mrq)	16.09%
Book Value Per Share (mrq)	10.47

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.25
Free Cash Flow (ytd)	-100.76M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Crinetics Pharmaceuticals Inc

Trade With A Regulated Broker